Evidence map›Paper›PMID 42682775›Full record

ReviewFrontiers in medicine2026

Factor XIII deficiency: an updated approach to diagnosis and management.

Rahaf Mahmoud Altahan

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rahaf Mahmoud AltahanHematology Unit, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Factor XIII deficiency (FXIIID) is a rare bleeding disorder that may be congenital or acquired and is associated with significant morbidity, particularly in its congenital form, including intracranial hemorrhage, impaired wound healing, and adverse pregnancy outcomes. Unlike other coagulation factor deficiencies, FXIIID is not detected by routine coagulation screening tests, contributing to delayed diagnosis and underrecognition. This review provides an updated overview of the epidemiology, molecular biology, clinical manifestations, laboratory diagnosis, and management of FXIIID. Particular emphasis is placed on contemporary diagnostic strategies, including the advantages and limitations of functional, antigen, inhibitor, and genetic assays, as well as preanalytical and analytical pitfalls that may affect test interpretation. Special attention is given to acquired FXIIID, emerging diagnostic challenges, and complex clinical scenarios, including pregnancy, neonatal care, surgery, and anticoagulation. Persistent knowledge gaps, including assay standardization and limited evidence supporting current recommendations for managing special scenarios, are also highlighted. Continued international collaboration and prospective data collection are needed to improve diagnosis, refine treatment strategies, and strengthen future evidence-based guidance.

Indexed as

acquired factor XIII deficiencycongenital bleeding disorderscongenital factor XIII deficiencyfactor XIIIrare bleeding disorders

Identifiers

PMID42682775
PMCPMC13530902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.